[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-339831-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-339831-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","genomic-profiling-of-a-multi-lineage-and-multi-passage-patient-derived-xenograft-biobank-reflects-heterogeneity-of-ovarian-cancer","Genomic proﬁling of a multi-lineage and multi-passage patient-derived xenograft biobank reﬂects heterogeneity of ovarian cancer","","Ovarian cancer shows inter- and intra-patient heterogeneity, leaving limited survival gains despite advances in biological and genetic understanding. Using multi-site sampling and a multi-lineage patient-derived xenograft (PDX) strategy, the study establishes a comprehensive PDX biobank from histologically and molecularly heterogeneous patients. Matched profiling confirms PDX fidelity to parental tumors, while multi-lineage models attribute PDX genomic disparities to spatial heterogeneity. DDRi screening reveals heterogeneous and acquired drug-resistant mechanisms driven by suppressed IFN response and activated Wnt/β-catenin signaling.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/genomic-profiling-of-a-multi-lineage-and-multi-passage-patient-derived-xenograft-biobank-reflects-heterogeneity-of-ovarian-cancer/339831/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/genomic-profiling-of-a-multi-lineage-and-multi-passage-patient-derived-xenograft-biobank-reflects-heterogeneity-of-ovarian-cancer/339831.png","ImageObject",300,407,{"name":42,"@type":43},"Oliver","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-24","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main goal of the study on ovarian cancer PDXs?","Question",{"text":63,"@type":64},"To establish and comprehensively profile a PDX biobank from histologically and molecularly heterogeneous ovarian cancer patients and to assess model fidelity and heterogeneity-driven genomic differences.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How do the authors evaluate whether PDX models recapitulate parental tumors?",{"text":68,"@type":64},"They perform comprehensive profiling of matched PDX and patient samples, showing that PDXs closely recapitulate parental tumors.",{"name":70,"@type":61,"acceptedAnswer":71},"What mechanisms underlie acquired DDR inhibitor (DDRi) drug resistance in the induced models?",{"text":72,"@type":64},"Induced drug-resistant models show suppressed interferon (IFN) response and activated Wnt/β-catenin signaling, which contribute to acquired DDRi drug resistance.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},339831,1790853211,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},8796095461610,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Article  \nGenomic proﬁling of a multi-lineage and multipassage patient-derived xenograft biobank reﬂects heterogeneity of ovarian cancer  \nAuthors  \nTianyu Qin (秦天予), Zhe Hu (胡哲), Li Zhang (张莉), ..., Kun Song (宋坤), Gang Chen (陈刚), Chaoyang Sun (孙朝阳)  \nCorrespondence  \n[songkun2001226@sdu.edu.cn](songkun2001226@sdu.edu.cn) (K.S.),  \n[tjchengang@hust.edu.cn](tjchengang@hust.edu.cn) (G.C.),  \n[suncydoctor@gmail.com](suncydoctor@gmail.com) (C.S.)  \nIn brief  \nQin et al. present an ovarian cancer PDX biobank consisting of 66 distinctive lineages derived from 53 patients. Histological, genetic, and phylogenetic analyses of multi-lineage and multipassage PDXs, in conjunction with multisite patient tumors, demonstrate the biobank’s ﬁdelity. Generation and interrogation of induced drug-resistant PDXs reveal DDR inhibitor resistance mechanisms.  \nd Establishment of a PDX biobank from histologically and molecularly heterogeneous OC  \nd Multi-lineage and multi-passage PDX analysis reveals model ﬁdelity  \nd Intra-patient spatial heterogeneity contributes to genomic disparities in PDX model  \nd Prolonged iterative exposure recapitulates drug resistance in PDX models in vivo  \nQin et al., 2024, Cell Reports Medicine 5, 101631  \nJuly 16, 2024 ª 2024 The Author(s) . Published by Elsevier Inc.  \n[https://doi.org/10.1016/j.xcrm.2024.101631](https://doi.org/10.1016/j.xcrm.2024.101631)  \nll  \nll  \nOPEN ACCESS  \nArticle  \nGenomic proﬁling of a multi-lineage  \nand multi-passage patient-derived xenograft biobank reﬂects heterogeneity of ovarian cancer  \nTianyu Qin (秦天予),1,2,6 Zhe Hu (胡哲),1,2,6 Li Zhang (张莉),1,2,6 Funian Lu (陆富年),1,2,6 Rourou Xiao (肖柔柔),3 Yiting Liu (刘依婷),1,2 Junpeng Fan (樊俊鹏),1,2 Ensong Guo (郭恩松),1,2 Bin Yang (杨斌),1,2 Yu Fu (付裕),1,2 Xucui Zhuang (庄绪翠),1,2 Xiaoyan Kang (康晓燕),1,2 Zimeng Wu (兀紫梦),1,2 Zixuan Fang (方紫璇),1,2 Yaoyuan Cui (崔耀元),1,2 Xingyuan Hu (胡杏媛),1,2 Jingjing Yin (尹静静),1,2 Miao Yan (颜秒),1,2 Fuxia Li (李福霞),4 Kun Song (宋坤),5,* Gang Chen (陈刚),1,2,* and Chaoyang Sun (孙朝阳)1,2,5,7,*  \n1Department of Gynecological Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, P. R. China  \n2National Clinical Research Center for Obstetrics and Gynecology, Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430010, P.R. China  \n3Department of Obstetrics and Gynecology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P. R. China  \n4Department of Obstetrics and Gynecology, First Afﬁliated Hospital of Shihezi University School of Medicine, Shihezi, Xinjiang 832008, P. R. China  \n5Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, Shandong 250012, P. R. China  \n6These authors contributed equally  \n7Lead contact  \n*Correspondence: [songkun2001226@sdu.edu.cn](songkun2001226@sdu.edu.cn) (K.S.), [tjchengang@hust.edu.cn](tjchengang@hust.edu.cn) (G.C.), [suncydoctor@gmail.com](suncydoctor@gmail.com) (C.S.) [https://doi.org/10.1016/j.xcrm.2024.101631](https://doi.org/10.1016/j.xcrm.2024.101631)  \nSUMMARY  \nOvarian cancer (OC) manifests as a complex disease characterized by inter-and intra-patient heterogeneity. Despite enhanced biological and genetic insights, OC remains a recalcitrant malignancy with minimal survival improvement. Based on multi-site sampling and a multi-lineage patient-derived xenograft (PDX) establishment strategy, we present herein the establishment of a comprehensive PDX biobank from histologically and molecularly heterogeneous OC patients. Comprehensive proﬁling of matched PDX and patient samples demonstrates that PDXs closely recapitulate parental tumors. By leveraging multi-lineage models, we reveal that the previously reported genomic disparities of PDX could be mainly attributed to intra-patient spatial heterogeneity instead of substantial model-independent genomic evolution. Moreover, DNA ","cbCaicz9HvnXl9Vj","https://ap.wps.com/l/cbCaicz9HvnXl9Vj","pdf",9224345,23,"English","# In brief\n## PDX biobank establishment and fidelity\n## Multi-lineage and multi-passage analysis\n## Spatial heterogeneity and genomic disparities\n## DDRi screening and drug-resistance mechanisms\n# Summary\n## Disease heterogeneity and study rationale\n## Biobank construction strategy\n## Recapitulation of parental tumors\n## Effects of intra-patient spatial heterogeneity\n## Interferon and Wnt/β-catenin in acquired DDRi resistance\n# Introduction\n## Limits of existing models and therapies","[{\"question\":\"What is the main goal of the study on ovarian cancer PDXs?\",\"answer\":\"To establish and comprehensively profile a PDX biobank from histologically and molecularly heterogeneous ovarian cancer patients and to assess model fidelity and heterogeneity-driven genomic differences.\"},{\"question\":\"How do the authors evaluate whether PDX models recapitulate parental tumors?\",\"answer\":\"They perform comprehensive profiling of matched PDX and patient samples, showing that PDXs closely recapitulate parental tumors.\"},{\"question\":\"What mechanisms underlie acquired DDR inhibitor (DDRi) drug resistance in the induced models?\",\"answer\":\"Induced drug-resistant models show suppressed interferon (IFN) response and activated Wnt/β-catenin signaling, which contribute to acquired DDRi drug resistance.\"}]","Genomic proﬁling of a multi-lineage and multi-passage patient-derived xenograft biobank reﬂects heterogeneity of ovarian cancer | PDF",1790032496,58,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e1c134ebc8138143dafe313086179dd3.webp",983,1276,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ad1ccad02c9bb6081cffc13717fbc1ad.webp",982,1275,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bac8aad001c51fbac8c286dd6ed39d1c.webp",981,1273,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/64e9133d86f7480ef6cb05b0db188e23.webp",980,1272]